Home › Trials › NCT06632327

Comparing treatment timing for lung cancer surgery

Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

PHASE3 · Alliance for Clinical Trials in Oncology · NCT06632327

This study is testing whether giving standard cancer treatment before and after surgery helps people with resectable stage II-IIIB lung cancer live longer and have fewer problems compared to only giving it after surgery.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment1100 (estimated)
Ages18 Years and up
SexAll
SponsorAlliance for Clinical Trials in Oncology (other)
Drugs / interventionsnivolumab, pembrolizumab, atezolizumab, chemotherapy, immunotherapy
Locations377 sites (Birmingham, Alabama and 376 other locations)
Trial IDNCT06632327 on ClinicalTrials.gov

What this trial studies

This phase III trial evaluates the effectiveness of administering standard therapy before and after surgery (perioperative) versus only after surgery (adjuvant) in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study aims to determine which treatment approach leads to better event-free survival and overall survival rates. Patients will receive chemotherapy and/or immunotherapy based on current standard care protocols, with various drug options available. The trial will also assess surgical outcomes and adverse events associated with each treatment arm.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed resectable stage IIA to IIIB NSCLC and an ECOG performance status of 2 or lower.

Not a fit: Patients with known EGFR or ALK alterations or those with advanced stage N2b or N3 lung cancer will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could identify a more effective treatment strategy for patients with resectable lung cancer, potentially improving survival rates.

How similar studies have performed: Other studies have explored similar treatment timing approaches in lung cancer, showing promising results, but this specific comparison is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologically or cytologically confirmed surgically resectable stage IIA to IIIB NSCLC according to the American Joint Committee on Cancer (AJCC) 9th edition (stage IIA to IIIB NSCLC up to single station N2, according to the AJCC 8th edition)

  \* Note: Patients with resectable stage N2a or T4 are eligible, but patients with stage N2b or N3 are not eligible. Patients with known EGFR or ALK alterations are excluded
* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (or Karnofsky ≥ 60%)
* No prior systemic treatment for NSCLC within 5 years except stage 1 and 2 cancers treated with curative intent
* No treatment for another malignancy within 3 years prior to registration, except for stage 1 or 2 cancers treated for curative intent; patients must be disease free for one year prior to registration. Patients with non-melanoma skin cancer, urothelial carcinoma in situ (Tis), noninvasive papillary carcinoma of the urinary bladder (Ta), prostatic intraepithelial neoplasia (PIN), ductal carcinoma in situ (DCIS) of the breast, or cervical intraepithelial neoplasia (CIN) of the uterine cervix are also eligible
* No active autoimmune disease, interstitial lung disease, or transplant that precludes safe treatment with immune checkpoint inhibitors
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

Where this trial is running

Birmingham, Alabama and 376 other locations

+327 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.